Skip to Content

Abaloparatide Dosage

Medically reviewed by Last updated on Jan 26, 2021.

Applies to the following strengths: 3120 mcg/1.56 mL

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Osteoporosis

80 mcg subcutaneously once a day

-Cumulative use of this drug and parathyroid hormone analogs (e.g., teriparatide) for more than 2 years during a patient's lifetime is not recommended.
-Patients should receive supplemental calcium and vitamin D if dietary intake is inadequate.

Use: For the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy; in postmenopausal women with osteoporosis, this drug reduces the risk of vertebral fractures and nonvertebral fractures

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

Data not available


-This drug caused a dose-dependent increase in the incidence of osteosarcoma, a malignant bone tumor, in animal studies. The effect was observed at systemic exposures ranging from 4 to 28 times the exposure in humans receiving the 80 mcg dose. It is unknown whether it can cause osteosarcoma in humans. Use is not recommended in patients at increased risk for osteosarcoma including those with Paget's disease of bone or unexplained elevations of alkaline phosphatase, open epiphyses, bone metastases or skeletal malignancies, hereditary disorders predisposing to osteosarcoma, or prior external beam or implant radiation therapy involving the skeleton. Cumulative use of this drug and parathyroid hormone analogs (e.g., teriparatide) for more than 2 years during a patient's lifetime is not recommended.

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

Administration advice:
-Administer as a subcutaneous injection into the periumbilical region of the abdomen; rotate the site of the injection every day.
-Administer at approximately the same time every day.
-Do not administer IV or IM.
-Administer the first several doses where the patient can sit or lie down if necessary, in case symptoms of orthostatic hypotension occur.

-This drug is supplied as a clear and colorless solution. Visually inspect for particulate matter and discoloration prior to administration. Do not use if solid particles appear or if the solution is cloudy or colored.
-Provide appropriate training to patients and caregivers on the proper use of the delivery pen.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.